Nanoparticle-detained toxins for safe and effective vaccination

Nature Nanotechnology

Volumn 8, Issue 12, 2013, Pages 933-938

  Hu, Che Ming J ^a   Fang, Ronnie H ^a   Luk, Brian T ^a   Zhang, Liangfang ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; CELL MEMBRANES; DETOXIFICATION; ECONOMIC AND SOCIAL EFFECTS; MAMMALS; METABOLITES; NANOPARTICLES;

BACTERIAL INFECTIONS; COATED NANOPARTICLES; ERYTHROCYTE MEMBRANE; HEAT DENATURATION; PARTICLE ENTRAPMENT; PORE FORMING TOXINS; PROTECTIVE IMMUNITIES; VIRULENCE FACTORS;

VACCINES;

ALPHA HEMOLYSIN; ANTITOXIN; NANOPARTICLE; NANOTOXOID HLA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL VIRULENCE; CONTROLLED STUDY; DENATURATION; DETOXIFICATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE MEMBRANE; HEAT; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ANIMALS; BACTERIAL TOXINS; DRUG DELIVERY SYSTEMS; HEMOLYSIN PROTEINS; HUMANS; MICE; NANOPARTICLES; SAFETY; VACCINATION;

EID: 84890564255     PISSN: 17483387     EISSN: 17483395     Source Type: Journal    
DOI: 10.1038/nnano.2013.254     Document Type: Article

References (30)

1. Kitchin, N. R. Review of diphtheria, tetanus and pertussis vaccines in clinical development. Exp. Rev. Vaccines 10, 605-615 (2011
2. Greenberg, R. N., Marbury, T. C., Foglia, G. & Warny, M. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 30, 2245-2249 (2012
3. Mortimer, E. A. Jr. Immunization against infectious disease. Science 200, 902-907 (1978
4. Holmgren, J. et al. Development of improved cholera vaccine based on subunit toxoid. Nature 269, 602-604 (1977
5. Gentschev, I., Dietrich, G. & Goebel, W. The E. coli alpha-hemolysin secretion system and its use in vaccine development. Trends Microbiol. 10, 39-45 (2002
6. Cover, T. L. & Blanke, S. R. Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nature Rev. Microbiol. 3, 320-332 (2005
7. Bubeck Wardenburg, J. & Schneewind, O. Vaccine protection against Staphylococcus aureus pneumonia. J. Exp. Med. 205, 287-294 (2008
8. Parish, H. J. & Cannon, D. A. Staphylococcal infection: Antitoxic immunity. Br. Med. J. 1, 743-747 (1960
9. Metz, B. et al. Identification of formaldehyde-induced modifications in proteins: Reactions with model peptides. J. Biol. Chem. 279, 6235-6243 (2004
10. Cryz, S. J. Jr, Furer, E. & Germanier, R. Effect of chemical and heat inactivation on the antigenicity and immunogenicity of Vibrio cholerae. Infect. Immunol. 38, 21-26 (1982
11. Vogel, F. R. Improving vaccine performance with adjuvants. Clin. Infect. Dis. 30(Suppl 3), S266-S270 (2000
12. Kennedy, A. D. et al. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J. Infect. Dis. 202, 1050-1058 (2010
13. Adhikari, R. P. et al. Novel structurally designed vaccine for S. aureus a-hemolysin: Protection against bacteremia and pneumonia. PLoS One 7, e38567 (2012
14. Jang, S. I. et al. Vaccination with Clostridium perfringens recombinant proteins in combination with Montanide ISA 71 VG adjuvant increases protection against experimental necrotic enteritis in commercial broiler chickens. Vaccine 30, 5401-5406 (2012
15. Kirkham, L. A. et al. Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines. Infect. Immunol. 74, 586-593 (2006
16. Hu, C. M. et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA 108, 10980-10985 (2011
17. Hu, C. M., Fang, R., Copp, J., Luk, B. & Zhang, L. A biomimetic nanosponge that absorbs pore-forming toxins. Nature Nanotech. 8, 336-340 (2013
18. Dobrovolskaia, M. A. & McNeil, S. E. Immunological properties of engineered nanomaterials. Nature Nanotech. 2, 469-478 (2007
19. Moon, J. J. et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nature Mater. 10, 243-251 (2011
20. Sun, C. et al. Circumventing anti-vector immunity using adenovirus-infected blood cells for repeated application of adenovirus vectored vaccines: Proof-ofconcept in rhesus macaques. J. Virol. 86, 11031-11042 (2012
21. Roberts, D. M. et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441, 239-243 (2006
22. Skean, J. D. & Overcast, W. W. Efficacy of staphylococcal vaccines to elicit antistaphylococcal alpha-hemolysin in dairy cows. J. Dairy Sci. 51, 1239-1242 (1968
23. Elamanchili, P., Diwan, M., Cao, M. & Samuel, J. Characterization of poly(D,Llactic- co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22, 2406-2412 (2004
24. Moon, J. J. et al. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc. Natl Acad. Sci. USA 109, 1080-1085 (2012
25. Inoshima, I. et al. A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. Nature Med. 17, 1310-1314 (2011
26. Moon, J. J., Huang, B. & Irvine, D. J. Engineering nano- and microparticles to tune immunity. Adv. Mater. 24, 3724-3746 (2012
27. Swartz, M. A., Hirosue, S. & Hubbell, J. A. Engineering approaches to immunotherapy. Sci. Transl. Med. 4, 148-149 (2012
28. Reddy, S. T. et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nature Biotechnol. 25, 1159-1164 (2007
29. Hubbell, J. A., Thomas, S. N. & Swartz, M. A. Materials engineering for immunomodulation. Nature 462, 449-460 (2009
30. Parodi, A. et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nature Nanotech. 8, 61-68 (2013 Diseases